Breast cancer (Tokyo, Japan)最新文献

{"title":"Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single-arm, open-label trial.","authors":"Riko Sato, Rena Kamohara, Tomohei Matsuo, Aya Sawa, Mai Okazaki, Sachie Hashimoto, Akiko Iguchi-Manaka, Hisato Hara, Kosuke Doki, Yuji Mukai, Masato Homma, Ryota Ishii, Kensuke Shimada, Hiroko Bando","doi":"10.1007/s12282-026-01828-5","DOIUrl":"10.1007/s12282-026-01828-5","url":null,"abstract":"<p><p>BACKGROUND: Although venlafaxine has shown efficacy for hot flashes in hormone receptor–positive breast cancer, evidence in Asian women (especially premenopausal) remains limited. Hot flashes reduce endocrine therapy adherence and severity may increase with ovarian suppression. We conducted a prospective, single-arm, open-label study to evaluate the efficacy and safety of venlafaxine in tamoxifen-treated patients with moderate-to-severe hot flashes. METHODS: Twenty patients received venlafaxine at 37.5 mg/day for 4 weeks, with optional escalation to 75 mg/day. Weekly hot flash scores, adverse events, and serum concentrations of tamoxifen, its metabolites, and venlafaxine (as well as CYP2D6 genotype associations) were assessed. Of the 20 patients, 17 were included in the primary efficacy analysis, 20 in the safety population for adverse events, and 18 in the pharmacokinetic analysis. RESULTS: At Week 4, hot flash scores declined by 49.8% from baseline (P < 0.001). Venlafaxine did not affect serum concentrations of tamoxifen or its metabolites. CYP2D6 intermediate metabolizers had higher venlafaxine concentrations than extensive metabolizers (P = 0.007), although symptom improvement occurred regardless of genotype. All adverse events were Grade 1–2. CONCLUSIONS: These findings demonstrate that venlafaxine safely and effectively alleviates hot flashes in hormone receptor-positive breast cancer patients undergoing tamoxifen-based endocrine therapy. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"459-468"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146129069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic model for pulmonary metastasis in patients with HER2-positive breast cancer: a population-based study.","authors":"Jun Pang, Bingbing Huang, Wanying Yan, Huijun He, Nvzhu Liao, Wenna Sun, Yaoquan Li, Lishan Luo, Wei Zeng","doi":"10.1007/s12282-026-01836-5","DOIUrl":"10.1007/s12282-026-01836-5","url":null,"abstract":"<p><p>BACKGROUND: Lung metastasis is an important adverse prognostic factor in patients with HER2-positive breast cancer. However, a lack of an accurate estimation of the prognosis of patients with lung metastasis and the validation of population-based models has been observed. In this study, we aimed to establish a nomogram based on the surveillance, epidemiology, and end results (SEER) database to determine the prognostic factors associated with lung metastasis and evaluate the individualized survival of patients with lung metastasis. METHODS: This study included 613 patients diagnosed with HER2-positive breast cancer with lung metastasis (HER2 + BC-LM) from the SEER database and randomly divided them into two groups: (1) training group (n = 432) and (2) test group (n = 181). Based on the univariate and multivariate Cox regression analyses, we assessed the impact of multiple variables on the survival of the patients in the training group and constructed a nomogram to predict the survival probabilities of the patients at 6 months, 1 year, and 2 years. Furthermore, the nomogram was validated by the concordance index (C-index) and calibration plots. RESULTS: A prognostic model for predicting the prognosis of patients with HER2 + BC-LM was established and validated. For the patients diagnosed with HER2 + BC-LM, the C-index (0.813 in the training group and 0.787 in the validation group, respectively) and calibration plots revealed that the prognostic accuracy and clinical applicability of the nomogram were acceptable. The surgical resection of the primary tumor and chemotherapy were found to be significantly associated with better overall survival (OS). CONCLUSION: A sensitive and discriminatory model was established to predict the OS of patients with HER2 + BC-LM. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"544-556"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146204643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to the editor: Risk of endometrial cancer among breast cancer survivors in Japan-a matched cohort study.","authors":"Chitose Kawamura, Masao Iwagami","doi":"10.1007/s12282-025-01817-0","DOIUrl":"10.1007/s12282-025-01817-0","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"557-558"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146014120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.","authors":"Min-Seung Park, Youngjin Youn, Jee Ah Kim, Eun Hye Cho, In-Gu Do, Hee-Yeon Woo, Hyosoon Park, Eun Young Kim, Min-Jung Kwon","doi":"10.1007/s12282-025-01818-z","DOIUrl":"10.1007/s12282-025-01818-z","url":null,"abstract":"<p><strong>Background: </strong>Circulating tumor DNA (ctDNA) has emerged as a prognostic biomarker for breast cancer, potentially offering a more comprehensive representation of tumor genetic heterogeneity. In this study, we assessed the prognostic and monitoring values of ctDNA at multiple clinical time points during diagnosis and therapy.</p><p><strong>Methods: </strong>A total of 119 patients with breast cancer underwent ctDNA analysis using next-generation sequencing, targeting 47 breast cancer-related genes at three predefined time points (baseline, post-neoadjuvant chemotherapy [post-NAC], and follow-up). Disease-free survival (DFS) was analyzed based on ctDNA status.</p><p><strong>Results: </strong>ctDNA was detected in 50.9% of patients at baseline, 25.0% post-NAC, and 58.3% during follow-up. ctDNA positivity was associated with worse DFS at baseline (hazard ratio [HR] 7.54, 95% CI: 1.71-33.17, P = 0.008), post-NAC (HR 3.54, 95% CI: 1.24-10.12, P = 0.018), and follow-up (HR 7.68, 95% CI: 0.98-59.97, P = 0.052). TP53 mutations were the most frequently observed, present in 37.5%, 14.8%, and 20.4% of patients at baseline, post-NAC, and follow-up, respectively. PIK3CA mutations were the second most common, detected in 11.6%, 4.5%, and 5.8% of patients, respectively. ctDNA positivity for these mutations consistently showed elevated HRs for disease progression across clinical time points (HR range, 2.73-20.49). ctDNA non-clearance was associated with the highest risk of disease progression (HR 81.09, P < 0.001) and remained the strongest independent prognostic factor in the multivariate analysis (HR 52.07, P < 0.001).</p><p><strong>Conclusions: </strong>ctDNA analysis provides significant clinical utility for prognostic stratification and disease monitoring in breast cancer management.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"377-385"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146095399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score^® test among node-negative early breast cancer patients in Japan.","authors":"Kei Koizumi, Ataru Igarashi, Mark Gouldson, Sandeep Bilthare, Sebastien Eymere, Gebra Cuyún-Carter, Steve Millen, Mariko Nomoto, Yoshie Onishi, Aki Kudo, Pieter Drost, Naoko Sugiyama, Tom Kanazawa Tang, Naoki Niikura","doi":"10.1007/s12282-026-01834-7","DOIUrl":"10.1007/s12282-026-01834-7","url":null,"abstract":"<p><p>BACKGROUND: The Oncotype DX Breast Recurrence Score® test is prognostic for distant recurrence in hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) early-stage breast cancer. It is the only multigene assay able to predict chemotherapy benefit, validated by evidence from randomized controlled trials. Using a Japanese public healthcare payer perspective, a cost-effectiveness analysis was conducted comparing the Oncotype DX® test to clinico-pathological risk assessment in women with node-negative (N0), HR+/HER2- early breast cancer. METHODS: A decision-tree stratified patients according to their Recurrence Score® (RS®) result and adjuvant chemotherapy allocation. A Markov model was used to capture lifetime costs and outcomes of the chosen treatment. Distributions of clinical risk in N0 patients were derived from the TAILORx trial. Distant recurrence probability conditional on RS result was calculated using TAILORx and NSABP-20 studies. Endocrine and chemoendocrine therapy selection was informed by a Clinical Expert Survey and the literature. Drugs and medical device costs were obtained from the Ministry of Health, Labour and Welfare. RESULTS: The Oncotype DX test was dominant (i.e. cost-saving and more effective) as it generated more quality-adjusted life-years (QALYs) (0.207) at a lower cost (-¥649,596) compared to clinico-pathological risk assessment in the overall population. Cost savings were primarily driven by a lower incidence of distant recurrence (-¥1,007,177). The Oncotype DX test was dominant in all subgroups except for one, which was cost-effective. CONCLUSIONS: Use of the Oncotype DX test to guide treatment decisions improves patient outcomes while reducing healthcare costs for N0 HR+/HER2- early-stage breast cancer in Japan. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"499-509"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146198392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infiltration of TIM4-positive intratumoral macrophages serves as an adverse prognostic factor in breast cancer.","authors":"Mio Yamaguchi-Tanaka, Kiyoshi Takagi, Miyu Takahashi, Ai Sato, Yuto Yamazaki, Minoru Miyashita, Takashi Suzuki","doi":"10.1007/s12282-026-01825-8","DOIUrl":"10.1007/s12282-026-01825-8","url":null,"abstract":"<p><strong>Background: </strong>T-cell immunoglobulin and mucin domain containing protein 4 (TIM4), a phosphatidylserine receptor primarily expressed on antigen-presenting cells, has been implicated in phagocytosis and immune regulation in various diseases, including malignancies. However, the significance of TIM4 in the breast cancer microenvironment remains unclear. In this study, we investigated the localization and clinical significance of TIM4 in breast cancer.</p><p><strong>Methods: </strong>We immunolocalized TIM4 in human breast carcinoma tissues using immunohistochemistry (IHC) and multiplex fluorescence-immunohistochemistry (F-IHC) and examined its correlation with clinicopathological parameters and clinical outcomes.</p><p><strong>Results: </strong>TIM4 was highly expressed in both carcinoma cells and stromal cells in human breast carcinoma tissues. Multiplex F-IHC revealed that TIM4 was co-localized with CD68, a macrophage marker, whereas no co-localization was observed between TIM4 and CD80 (an M1 macrophage marker) or CD163 (an M2 macrophage marker). Prognostic analysis of 171 breast carcinoma tissues by IHC revealed that infiltration of TIM4-positive stromal cells was associated with an aggressive tumor phenotype, including increased proliferative and invasive potential, as well as poorer clinical outcomes. In contrast, TIM4 immunoreactivity in carcinoma cells showed no significant correlation with clinical outcomes.</p><p><strong>Conclusions: </strong>These findings suggest that infiltration of TIM4-positive macrophages serves as a strong prognostic indicator in breast cancer and that TIM4 may represent a novel marker for tumor-promoting macrophages.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"436-447"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146014099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real world experience of intraoperative radiation therapy (IORT) during lumpectomy for early-stage breast cancer: retrospective data from a single large institutional observational study.","authors":"Christophe Scherer, Vivien Fung, Dimitri Anzellini, Mattia Falchettto Osti, Virginie Doridot, Xavier Muracciole, Mario Nappa, Benoît Mesurolle, Gokoulakrichenane Loganadane","doi":"10.1007/s12282-026-01824-9","DOIUrl":"10.1007/s12282-026-01824-9","url":null,"abstract":"<p><strong>Background: </strong>We report outcomes of patients who received intraoperative radiation therapy (IORT) using 50 kV after lumpectomy and sentinel lymph node biopsy.</p><p><strong>Methods: </strong>Women with age > 45 and post-menopausal status, localized, unifocal, invasive breast carcinoma were included in the study. Patients were diagnosed by needle biopsy, and suitable for wide local excision of invasive ductal carcinoma without nodal involvement on conventional examination (cT1 and small cT2 ≤ 3.5 cm, cN0, M0). Overall, 489 patients who received adjuvant IORT after breast-conserving surgery were identified between March 2016 to June 2023. The median age was 68 years (range 49-93). The median tumor size was 8 mm (0-40 mm). Adjuvant whole breast adiation therapy (WBRT), chemotherapy and endocrine were additionally offered in 36 patients (7.4%), 12 (2.4%) and 384 patients (78.5%) respectively.</p><p><strong>Results: </strong>After a median follow-up of 36 months (range, 0-100), the 3-year LR was 1.4% (95% CI 0.6-3.1%). The 3-year LRFS, LRRFS, and PFS were each 97.1% (95% CI 94.6-98.5%), while the 3-year MRFS and OS were both 98.3% (95% CI 96.1-99.2%). The 3-year outcomes did not differ significantly between the IORT and IORT + WBRT cohorts. Patients who did not receive ET (n = 104) experienced a significantly higher rate of local recurrence compared with those who received ET (n = 384) (3-year LR 4.0% vs. 0.7%; p = 0.01). LRFS and LRRFS showed borderline significance (5-year LRFS 96.9% vs. 100%; p = 0.05). MRFS, PFS, and OS did not differ significantly between the two groups.</p><p><strong>Conclusions: </strong>Preliminary 3-year results show that IORT with 50 kV achieves excellent local control in selected early-stage breast cancer patients. Endocrine therapy reduced local recurrence, while WBRT added no significant benefit, underscoring the need for longer follow-up.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"426-435"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146042417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).","authors":"Shigenori E Nagai, Masaya Hattori, Tetsuhiro Yoshinami, Hiroko Masuda, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwase, Miki Yamaguchi, Takafumi Sangai, Shinsuke Sasada, Takanori Ishida, Manabu Futamura, Yasuaki Muramatsu, Nobuyoshi Kosaka, Norikazu Masuda","doi":"10.1007/s12282-025-01787-3","DOIUrl":"10.1007/s12282-025-01787-3","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"559-568"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146055843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"tRNA modification genes are associated with genomic instability, proliferative programs, and poor prognosis in breast cancer.","authors":"Yusuke Otani, Atsushi Tanaka, Anna Rogachevskaya, Akira Ohtsu, Vanessa D Chin, Tirso Peña, Shinichi Toyooka, Hiroyoshi Doihara, Atsushi Fujimura","doi":"10.1007/s12282-026-01830-x","DOIUrl":"10.1007/s12282-026-01830-x","url":null,"abstract":"<p><p>The modifications of transfer RNA (tRNA) add an extra layer of post-transcriptional gene regulation in cancer biology. While translation initiation and termination have been extensively studied, the role of tRNA modifications in elongation remains largely unexplored. These chemical changes, particularly in the anticodon loop, enhance codon–anticodon pairing and translation fidelity, but their impact on cancer, especially breast cancer, is not well defined. We analyzed 73 tRNA modification–related genes across 33 TCGA cancer types and breast cancer subtypes by integrating transcriptomic and proteogenomic data. These genes were enriched among poor-prognosis markers in many cancers, with strong associations in HER2-positive and Luminal A breast cancers. tRNA modification activity was positively correlated with genomic instability metrics and proliferative pathways, and negatively with immune-related pathways, patterns most evident in ER-positive and Luminal breast cancers. Proteogenomic analysis confirmed RNA–protein concordance for most genes, and higher protein-based modification scores were linked to increased stemness and chromosomal instability. Three genes, FTSJ1, TRMT2B, and ELP1, showed strong prognostic relevance, influencing chromatin regulator ZNF518A and immune-related factor PPARGC1A. Our findings indicate that modifications of tRNA during the elongation phase of protein synthesis are not merely passive but actively contribute to cancer biology. These changes may promote tumor growth, destabilize the genome, and help malignant cells evade immune detection. Together, these insights emphasize tRNA modifications as promising targets for new therapeutic strategies, especially for aggressive breast cancer subtypes where treatment options are still limited.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"523-535"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An investigation to identify the factors for negative sentinel lymph node metastasis in early breast cancer cases.","authors":"Reiki Nishimura, Yuichi Ueda, Hiroshi Kiyohara, Mayumi Funagayama, Naoko Ikeda, Aya Kato, Hideaki Tokiniwa, Ryutaro Higashi, Mayumi Nakahara, Hiromi Ifuku, Tohru Hayashi, Yasuaki Sagara, Yoshiaki Sagara, Shinji Ohno","doi":"10.1007/s12282-026-01832-9","DOIUrl":"10.1007/s12282-026-01832-9","url":null,"abstract":"<p><p>BACKGROUND: Sentinel Lymph Node Biopsy (SLNB) in breast cancer (BC) is a standard procedure. Omission of SLNB in BC is an evolving area in clinical practice and a reasonable option. A retrospective study was conducted to identify cases of negative SLNs. METHODS: A total of 1,956 patients who underwent SLNB for cN0 invasive BC and who did not undergo preoperative chemotherapy were included in this retrospective study. Pathological diagnosis using frozen sections or the OSNA method was used for the diagnosis of SLNs. A multivariate analysis of factors for negative SLNs was performed using logistic regression analysis. RESULTS: Metastasis to SLNs was observed in 379 cases (19.4%). SLN metastasis was not associated with ER, PgR, and HER2 status. A multivariate analysis revealed that the significant factors for negative SLNs were age > 50 years, tumor size ≤ 2 cm and HG of 1. The incidence of SLN metastasis in Luminal B type was significantly higher than the other subtypes, and cases with breast conserving surgery had a significantly lower metastatic rate than total mastectomy. The disease-free survival rate of cases with the above-mentioned factors was favorable regardless of the SLN status. CONCLUSION: Metastasis to SLNs was found in 19.4% of cN0 BC cases. Factors related to negative SLNs were age > 50 years, tumor size ≤ 2cm, and HG of 1, and a positive SLN rate was significantly higher in the Luminal B subtype. The DFS for cases with the above factors was highly favorable. Therefore, conducting SLNB will depend on the above-mentioned characteristics. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"536-543"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146145895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}